Moderna's AI-assisted mRNA cancer treatment succeeds in Phase 3 trial

KyeGomezB · x · 2026-08-20

Moderna and Merck's AI-assisted personalized mRNA cancer treatment has succeeded in a Phase 3 trial. The therapy sequences patient tumors, uses AI to identify mutations likely to trigger an immune response, and produces individualized mRNA treatments encoding up to 34 neoantigens. In the earlier Phase 2 trial for high-risk melanoma, it reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59%.

Related event: Moderna's AI-Designed Personalized mRNA Cancer Vaccine Wins Phase III, Stock Soars(17 posts)→

Original post →

More from Apps

Apps channel →